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ABSTRACT 
The heterogeneous manifestations of the MYH9-related disorder (MYH9-RD), 
characterized by macrothrombocytopenia, Döhle-like inclusion bodies in leukocytes, 
bleeding of various severity with in some cases ear, eye, kidney and liver involvement 
make the diagnosis for these patients still challenging in clinical practice. We collected 
phenotypic data and analysed the genetic variations in more than 3,000 patients with a 
bleeding or platelet disorder. Patients were enrolled in the BRIDGE-BPD and 
ThromboGenomics Projects and their samples processed by high throughput sequencing 
(HTS). We identified 50 patients with a rare variant in MYH9. All patients had 
macrothrombocytes and all except two had thrombocytopenia. Some degree of bleeding 
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diathesis was reported in 41 patients. Eleven patients presented hearing impairment, three 
renal failure and two elevated liver enzymes. Among the 28 rare variants identified in 
MYH9, 12 were novel. HTS was instrumental to diagnose 23 patients (46%). Our results 
confirm the clinical heterogeneity of MYH9-RD and show that, in the presence of an 
unclassified platelet disorder with macrothrombocytes, MYH9-RD should always be 
suspected. A HTS-based strategy is a reliable method to reach a conclusive diagnosis of 
MYH9-RD in clinical practice. 
Graphical Abstract 
MYH9-related disorder diagnosis is still challenging in clinical practice. We 
analysed the genetic variations in more than 3,000 patients with a bleeding or 
platelet disorder and identified 50 patients with a rare variant in MYH9. In the 
presence of an unclassified platelet disorder with macrothrombocytes, MYH9-RD 
should always be suspected. 
 
Key words: MYH9-related disorders, variant classification, clinical diagnosis, high 
throughput next generation sequencing, genomics, ACMG Guidelines 
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INTRODUCTION  
Non-muscle myosin heavy chain 9 related disorder (MYH9-RD) is a rare autosomal-
dominant syndrome characterized by large/giant platelets and thrombocytopenia 
associated with the presence of Döhle-like inclusion bodies in neutrophils (Kunishima, et 
al 2003). Clinical manifestations include a mild to moderate bleeding tendency (Orsini, et 
al 2017) and the risk of developing progressive nephropathy, sensorineural deafness, pre-
senile cataract or alteration of liver enzymes during infancy or adult life (Balduini, et al 
2011, Pecci, et al 2012, Pecci, et al 2018). The disease is caused by heterozygous variants 
in MYH9, the gene coding for the heavy chain of non-muscle myosin of class IIA 
(NMMHC-IIA), a 1,960 amino acid residue protein involved in platelet cytoskeletal 
contraction, granule secretion, and in the Rho GTPases and Ca2+/calmodulin signaling 
pathways (Vicente-Manzanares, et al 2009). MYH9 is located on chromosome 22q12-13 
and is composed of 41 exons. The coding region from exons 2 to 19 forms the globular 
head domain (HD), exon 20 for the neck region, and exons 21 to 40 for the coiled-coil 
tail domain (TD). The final 34 amino acid residues of the C-terminal non-helical tail 
domain (NHTD) are encoded by exon 41. 
101 MYH9 variants are listed in the Human Gene Mutation Database (HGMD, public 
version, as of July 2019, Stenson, et al 2017): 72 missense/nonsense, 4 splicing 
substitutions, 17 small deletions/insertions, 8 large deletions/insertions. One very large 
deletion of 1220 bp involving exon 26 and some cases of somatic or germinal mosaicism 
have also been described (Gresele, et al 2013, Kunishima, et al 2005, Kunishima, et al 
2009). 
Genotype-phenotype correlation studies in MYH9-RD patients have reported that variants 
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in the HD are associated with more severe thrombocytopenia and a higher frequency 
and/or a more rapid progression of nephropathy and deafness than variants in the TD, 
with the amino acid substitution p.Arg702Cys resulting in the most severe phenotype 
reported to date (Pecci, et al 2014, Pecci, et al 2008b, Saposnik, et al 2014). However, 
some exceptions exist: the p.Asp1424His variant which lies in the TD, is also associated 
with a high risk of developing syndromic manifestations. Moreover, patients carrying 
variants at the interface between the SH3-like motif and the motor domain (MD) of the 
HD (SH3/MD interface), present a mild clinical phenotype consisting of mild 
macrothrombocytopenia and delayed risk of sensorineural deafness (Pecci, et al 2014). 
The diagnosis of MYH9-RD requires skilled laboratory investigations, including the 
correct assessment of the degree of thrombocytopenia, made difficult by the abnormal 
size of platelets, the identification of macrothrombocytes, and the determination of the 
presence of Döhle-like inclusion bodies in neutrophils on a blood smear (Balduini, et al 
2003). The latter test is performed by May-Grünwald-Giemsa (MGG) staining or through 
the identification of NMMHC-IIA aggregates by immunofluorescence (Kunishima, et al 
2003, Pecci, et al 2008b), a test which is not available in most of the hematology 
diagnostic laboratories despite its high sensitivity. Moreover, high variability in the 
syndromic manifestations can complicate the interpretation of the clinical presentation. 
The identification of the causal MYH9 variant in a patient is key to reach a conclusive 
diagnosis, predict the course of extra-hematological symptoms and consequently 
implement a personalized clinical monitoring and therapeutic approach (Pecci, et al 
2008a, Pecci, et al 2010a). HTS techniques represent a comprehensive and cost-effective 
strategy for a precise diagnosis of inherited bleeding, thrombotic and platelet disorders 
(BPDs) (Simeoni, et al 2016, Zhang, et al 2016). The efficacy of HTS in patients with 
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uncharacterized macrothrombocytopenia has been recently demonstrated (Rabbolini, et al 
2017). Here, we report the patients with a rare MYH9 variant discovered after genome 
sequencing of 1,481 subjects enrolled in the BRIDGE-BPD study and 1,550 patients 
enrolled in the clinical diagnostic ThromboGenomics study (Simeoni, et al 2016). We 
identified 28 causal rare MYH9 variants in 50 patients (44 index cases), 20 with a known 
diagnosis of MYH9-RD (based on the presence of macrothrombocytopenia, Döhle-like 
bodies and an extra-haematological phenotype in some of them) with no genetic 
confirmation, 11 with an already suspected but not confirmed MYH9-RD and 19 in whom 
MYH9-RD was not previously suspected despite an expert evaluation of their clinical and 
laboratory data. We describe the 28 MYH9 variants identified, 12 of which are novel and 
classify the variants for pathogenicity and contribution to phenotype. We also describe 
the phenotypic profiles of this MYH9-RD cohort adding new insight into genotype-
phenotype correlations and expanding the knowledge on this rare inherited platelet 
disorder.  
METHODS 
Patient cohort 
Patients gave their written informed consent and were enrolled through two main 
projects: the NIHR BioResource - Rare Diseases study (specifically, the BRIDGE-BPD 
project) and the clinical diagnostic ThromboGenomics study. The BRIDGE-BPD project 
includes patients with rare inherited BPDs of unknown etiology who were screened 
mainly by genome sequencing and a small subset by exome sequencing. DNA samples 
from BPD patients with clinical and laboratory phenotypes indicative of a particular 
molecular etiology were sequenced using the ThromboGenomics HTS test. Inclusion 
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criteria have been previously described (Simeoni, et al 2016, Westbury, et al 2015). 
Ethics authorities and approval numbers are provided in Supp. Table S1. 
Clinical and laboratory phenotypes  
Clinical and laboratory phenotypes were submitted by the referring clinicians as Human 
Phenotype Ontology (HPO) terms, as previously described (Westbury, et al 2015). The 
severity of bleeding was coded as numerical scores using the MCMDM-1 VWD Bleeding 
Assessment Tool 
(http://www1.wfh.org/docs/en/Resources/Assessment_Tools_MCMDM-1VWD.pdf). 
Centralized analysis of blood smears for the identification of Döhle-like inclusion bodies 
in patients with previously not performed or negative detection of Döhle-like inclusion 
bodies was performed by two independent centres. Blood films obtained from patients 
and from healthy controls were randomly analysed by two operators blindly. Inclusions 
in neutrophils were classified as type I, II and III based on their size, shape and pattern of 
distribution (Kunishima, et al 2003, Pecci, et al 2008b). Information on hearing 
impairment, renal and liver dysfunctions were also collected. 
Variant prioritisation and assessment 
Sequencing results were processed by using a single analysis approach and filtering as 
previously described (Greene, et al 2016, Simeoni, et al 2016) (see also Supporting 
Information). An average of 5 variants per patient remained after the bioinformatics 
analysis and each of these variants was assessed following the ACMG Guidelines 
(Richards, et al 2015) by a Multi-Disciplinary Team (MDT) composed of clinicians, 
clinical geneticists, bioinformaticians and clinical scientists. The Congenica™ software 
(Congenica Ltd., Hinxton, UK) was used to visualise the data and assign pathogenicity 
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and contribution to phenotype to each variant based on the clinical picture, predicted 
consequence for the protein, presence in the Human Gene Mutation Database (HGMD 
(Stenson, et al 2017)) and allele frequency in control datasets as the Exome Aggregation 
Consortium (ExAC) (Karczewski, et al 2017) and the genome Aggregation Database 
(gnomAD) (Lek, et al 2016)). The MDT also evaluated the Minor Allele Frequency 
(MAF) of the variants found in patients with aggregate data from more than 13,000 
individuals enrolled in other non-BPD BRIDGE projects. The LRG transcript 
LRG_567t1 (NM_002473.5, ENST00000216181.10) was used as reference sequence. 
Variants and their pathogenicity have been deposited in ClinVar under accession 
numbers SCV000891130 to SCV000891157. They are accessible by searching for the 
accession number (e.g. SCV000891130) or with the keywords “MYH9 AND NIHR AND 
BioResource”(https://www.ncbi.nlm.nih.gov/clinvar/?term=MYH9+AND+NIHR+BioRe
source). 
RESULTS 
Novel MYH9 variants 
3,031 patients were enrolled in the BRIDGE-BPD and ThromboGenomics studies and 
screened for rare variants in the MYH9 gene. We found 74 individuals with a variant in 
the MYH9 gene, however only 50 patients were considered for this study. The remaining 
24 were excluded for the following reasons: 1) the MYH9 variant was also present in 
other non-BPD patients; 2) the platelet disorder and/or phenotype was not compatible 
with MYH9-RD (e.g. thrombocytosis, no large platelets); 3) the phenotype was explained 
by the presence of a causal variant in another gene; 4) the MYH9 variant was also 
identified in an unaffected family member. All the patients excluded from this study and 
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the reasons for their exclusion are shown in detail in Supp. Table S2.  
In the 50 patients analysed, of whom 44 are index cases, we found 28 MYH9 variants, 
namely 21 missense, three frameshifts, two stop gains, one in-frame deletion and one in-
frame insertion. The variants identified were positioned in 11 of the 41 exons of the 
MYH9 gene (Figure 1). Of the 28 variants, 12 are novel as absent from the HGMD 
database (public version, as of July 2019, Stenson, et al 2017), the literature and all other 
publicly accessible MYH9-RD databases at the time of the analysis (Table 1). Of the 
novel variants, three affect the SH3/MD interface of the globular MYH9 head, including 
a new c.97T>G transversion in exon 2, leading to p.Trp33Gly amino acid change, an in-
frame deletion p.Asp37_Ser39del and one missense variant p.Phe41Ser caused by the 
c.353T>C transition. In silico protein modelling predicts that these three variants may 
disturb the hydrophobicity of the SH3/MD interface (Supp. Figure S1). We also found 
eight novel variants localized in the coiled-coil domain. These include one missense 
variant p.Glu921Lys and a nonsense variant p.Gln890Arg*, leading to a premature stop 
codon causing the formation of a shorter MYH9 protein of 890 amino acids, both in exon 
22; one in-frame insertion p.Gln1068_Leu1074dup in exon 25 and five missense variants, 
p.Ser1195Leu in exon 27, p.Glu1421Ala and p.Gln1434His in exon 31, p.Asp1649Gly 
and p.Met1678Val in exon 33. In the non-helical tail domain of the protein, we found one 
further novel variant and a frameshift leading to a premature stop in the protein, 
p.Gly1938Alafs*10. The read coverage of whole genome sequencing (WGS) and 
targeted sequencing results for the 12 novel variants (in 11 patients) is shown in Supp. 
Figure S2. 
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Variant pathogenicity and contribution to phenotype  
The MDT assigned pathogenicity and contribution to phenotype to each variant 
according to the clinical features of each patient following the ACMG Standards and 
Guidelines (Richards, et al 2015) (shown in Table 1). The choice of the transcript for 
variant reporting was based on transcript and protein lengths, and expression in blood 
cells according to the Blueprint data (Javierre, et al 2016). Eleven MYH9 transcripts are 
expressed in the different blood cells, but only three of them are protein coding. 
ENST00000216181 (NM_002473, LRG_567t1) is the longest transcripts (7501 base 
pairs (bp), corresponding to a protein with the expected 1960 amino acids (aa) length), 
with an equivalent in the RefSeq database (NM_0024736). This is the most expressed 
transcript in platelets, while its expression is lower in neutrophils and megakaryocytes 
and much lower in erythroblasts. Of the two remaining protein coding transcripts, 
ENST00000401701 is much shorter (789 bp, 218aa) and markedly less expressed; 
ENST00000456729 is also shorter (449 bp, 103aa) and absent (log2(FPKM)<1) in blood 
cells (Supp. Figure S3). For these reasons, ENST00000216181 (NM_002473) was used 
for variant reporting. This is also the transcript subsequently selected by LRG 
(LRG_567t1). 
The MDT classified the novel variants as follows: the three variants in exon 2 found in 
patients 1, 2 and 3, as likely pathogenic (in patient 1) and variant of uncertain 
significance (VUS) (in patients 2 and 3) with full contribution to phenotype. The stop 
gain p.Gln890Arg*, in patient 20, was classified as VUS with full contribution to the 
phenotype. Based on the high impact of the variant on the MYH9 protein causing a 
premature stop, the variant might be considered to be likely pathogenic. However, we 
have not been able to perform any functional tests due to the difficulties of recalling the 
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86 year old patient, thus we remained conservative and classified this variant as VUS. 
The in-frame insertion Gln1068_Leu1074dup and the frameshift variant, 
p.Gly1938Alafs*10, were considered VUS and likely pathogenic with full contribution to 
the phenotype, respectively. The six novel missense variants (present in patients 28-29-
37-39-40) identified in the coiled-coil domain of the MYH9 protein were classified as 
VUSs with full contribution to phenotype. The referring clinicians of these five patients 
with a VUS variant, were re-contacted to arrange co-segregation studies. Pedigree 
analysis was possible only for two of these patients. This has confirmed, in patient 28, the 
absence of the variant in the non-affected mother and in patient 39 the presence of the 
same variant in the daughter affected with mild thrombocytopenia. The pathogenicity and 
contribution to phenotype assigned to the remaining non-novel variants are listed in 
Table 1.  
For all the variants identified in this study we investigated the evolutionary conservation 
in the MYH9 protein domains. We found that all pathogenic, likely pathogenic and VUS 
variants affect highly conserved amino acid residues providing further confidence that the 
variants identified have an impact on MYH9 protein function and consequently on the 
patients’ phenotypes (Figure 2). 
Immunofluorescence analysis 
At enrolment, the presence of Döhle-like inclusion bodies was reported only in 21 (42%) 
of the 50 patients analysed. Given that the Döhle-like bodies are reported to be invariably 
present in MYH9-RD patients, at least when analysed by immunofluorescence, we 
recalled the remaining 29 patients, initially labelled as Döhle-like bodies negative, for a 
centralized blood smear analysis (Supp. Table S3). Of these 29 patients, we obtained a 
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fresh blood smear from 18 patients. An abnormal neutrophils MYH9 distribution was 
found in all 18 (100%) patients when analysed by immunofluorescence and in 11 patients 
(61%) when analysed by the MGG staining, in accordance with previous results 
(Balduini, et al 2011).  
Immunofluorescence was performed for all the 11 patients with novel variants, except for 
those in which the Döhle-like bodies were previously identified (patients 2, 3, 21, 50) and 
in patients 37 and 39 not available for further analysis. In the remaining five patients, we 
obtained the following results: in patients 1 and 20, neutrophils had circular to oval 
shaped cytoplasmic spots that have been classified as type II inclusions. In patients 28 
and 40, neutrophils had speckled inclusions and in patient 29 inclusions resembled small 
dots scattered throughout the cytoplasm inclusions were classified as type III.  
In conclusion, 33% of the all the 18 patients re-analyzed had type II inclusions and 67% 
type III myosin IIA inclusions (Supp. Table S3). An example of the altered NMMHC-
IIA distribution in neutrophils in patients with a pathogenic variant and VUS is shown in 
Figure 3.  
Phenotypic description of the MYH9-RD cohort and genotype-phenotype correlation 
Our cohort includes 21 males and 29 females from 44 unrelated pedigrees. The median 
age at diagnosis was 20 years (range 1-76). Over a third (19) of the patients were enrolled 
with a diagnosis of ‘unclassified platelet disorder’ while the remaining (31) had a 
suspected (11) or known (20) but not confirmed MYH9-RD, based on family history, 
presence of large/giant platelets, thrombocytopenia, presence of Döhle-like bodies and/or 
extra-hematological symptoms. 
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Macrothrombocytes were present in all patients, while thrombocytopenia, with various 
degrees of severity, was present in all but two patients (17 and 40). The median platelet 
count was 54x109/L (8-220x109/L) from automated measurements and 48.5x109/L by 
microscopic assessment, although the latter was only available for 8 patients (Supp. 
Table S4). The mean platelet volume (MPV) values are shown in Supp. Table S5. Three 
cases had a normal MPV when measured by automatic blood cell counting, however 
macro-thrombocytes were noticed upon examination of their blood smears (Greinacher, 
et al 2017, Kunishima, et al 2001a). Haematological and non haematological symptoms 
are shown in Figure 4. Bleeding symptoms, mostly mild mucocutaneous bleeding, were 
reported in 82% of the patients (41 out of 50). Bleeding scores, calculated by the 
MCMDM-1 VWD Bleeding Assessment Tool, are shown in Supp. Table S6. Of the 29 
females enrolled, 11 (38%) had menorrhagia, one of the most common symptoms 
reported by women with congenital platelet disorders. 
Genotype-phenotype correlations were analysed by plotting the seven HPO terms 
representing the major MYH9-RD clinical features against the exons in which both 
previously described and novel MYH9 variants were found (Supp. Figure S4). We first 
investigated the correlation between the position of variants in the MYH9 protein and the 
degree of thrombocytopenia, by dividing patients in two groups according to platelet 
count below (severe/moderate) or above 50x109/L (mild). We found that 39% of the 
patients with severe thrombocytopenia have a variant affecting exons in the HD and 61% 
of the individuals had instead a variant in the coiled coil domain. Genotype-phenotype 
correlations were also studied for the extra-hematological manifestations of MYH9-RD. 
Details on how patients were screened for hearing impairment, renal dysfunction and 
liver enzymes alteration are summarised in Supp. Table S7. Nephropathy was reported 
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in patients 8 and 17, who carry p.Ser96Leu and p.Arg718Trp variants, respectively. 
Patient 8 also has hearing impairment. However, five other patients (10% of this cohort), 
two unrelated individuals carrying the same variant, p.Ser96Leu (patients 7 and 9), and 
three pedigree members of case 17, carrying the p.Arg718Trp, did not present any of 
these non-hematological features. Hearing impairment was present in 22% of the 
patients: 8% with variants involving the HD, as expected, and 14% involving the coiled-
coil and the NHT domains (Balduini, et al 2012, Pecci, et al 2014, Pecci, et al 2008b). 
Variants observed in patients with bleeding symptoms were randomly distributed across 
the MYH9 domains, confirming a lack of genotype-phenotype correlation for the 
bleeding phenotype (Pecci, et al 2014, Saposnik, et al 2014). Moreover, no correlation 
was found even between platelet count and bleeding tendency (Supp. Figure S5). 
DISCUSSION 
The MYH9-RD, although rare, is considered the most frequent inherited 
macrothrombocytopenia. In Italy, where a large active patient registry was established in 
2006, MYH9-RD has an estimated frequency of 1 in 312,000, representing 12% of the 
inherited thrombocytopenias (Balduini, et al 2012, Pecci, et al 2014). The complexity and 
variability of patients’ phenotypes can make the diagnosis of MYH9-RD rather 
challenging, even by skilled clinicians at specialist centres. As a consequence, a 
significant number of patients with MYH9-RD are initially misdiagnosed as immune 
thrombocytopenic purpura (ITP), and thus subjected to ineffective and potentially 
harmful treatments, or classified as inherited platelet disorder of unknown origin. In this 
scenario, HTS techniques may represent a reliable method for the diagnosis of MYH9-
RD. 
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The present study represents the first systematic analysis of MYH9 variants by HTS 
analysis in a large cohort of patients and controls enrolled from over 100 centres 
worldwide. Here, we report 50 MYH9-RD patients with 28 rare variants in MYH9 found 
in a group of 3,031 patients (of whom 764 were classified as having thrombocytopenia) 
and over 13,000 controls.  
In agreement with previous studies, 75% of the variants identified (21 out of 28) are 
annotated in the most commonly affected MYH9 exons (Pecci, et al 2014, Pecci, et al 
2008b, Saposnik, et al 2014). 
We identified 12 novel variants affecting MYH9 in highly conserved amino acid residues, 
including eight missense variants (one in a previously described amino acid residue but 
with a different nucleotide change (Jang, et al 2012, Kahr, et al 2009), one inframe 
deletion, one stop gain, one inframe insertion and one frameshift. Patients carrying the 
eight missense variants did not show extra-hematological symptoms, had a platelet count 
ranging from 15 to 96x109/L and three of them (1, 20, 21) had a history of excessive 
bleeding. The in frame deletion, Asp37_Ser39del, was found in a 31-year-old man with 
no bleeding symptoms, moderate thrombocytopenia and no extra-hematological 
symptoms. The new pathogenic stop codon in the coiled-coil domain, Gln890Arg*, 
leading to a large deletion of 1070 amino acids in the MYH9 protein was found in a 86-
year-old man who was originally diagnosed as an “unclassified platelet disorder”, with 
mild thrombocytopenia (88x109/L), no extra-hematological manifestations and a 
pathologic bleeding score due to major bleeding after surgery. We have not been able to 
test the presence of the truncated MYH9 protein in this patient’s cells, and a non classical 
distribution of NMMHC-IIA, with just small punctuate clusters (Althaus, et al 2009) was 
observed by IF- and MGG-staining in granulocytes (Supp. Figure S6). We also report 
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the first in-frame insertion, Gln1068_Leu1074dup. The same amino acids were 
previously described to be involved in an in-frame deletion in two patients (Ishida, et al 
2013, Saposnik, et al 2014). This was found in a young girl who presented with moderate 
thrombocytopenia (70x109/L), large platelets and moderate/severe bleeding (Bleeding 
score 7), similarly to the previously published cases, but with no current extra-
haematological symptoms. In contrast, the two patients previously described present 
several extra-hematological features like hearing loss since childhood, congenital 
cataracts and mild proteinuria in a 59 year-old woman (Saposnik, et al 2014) and end-
stage renal disease and bilateral hearing loss in a 27 year-old woman (Ishida, et al 2013). 
The novel frameshift, Gly1938Alafs*10, located in a known mutational hot spot, was 
found in a patient with severe thrombocytopenia (16x109/L), large platelets and mild 
bleeding.  
All the variants were discussed in MDT meetings and pathogenicity and contribution to 
phenotype assigned according to the ACMG Guidelines. The novel variants were labelled 
as pathogenic or likely pathogenic when supported by strong evidences, including the 
impact of the variant on the protein, the presence of strong MYH9-RD phenotype and/or 
another MYH9-RD feature and, when possible, by pedigree analysis. In all the remaining 
cases, the novel variants were classified as VUS. Previously reported variants were 
classified mainly as pathogenic. One variant, initially classified as VUS, was re-classified 
as benign (patient 71 in Supp. Table S2), one variant initially VUS to a likely pathogenic 
(in patients 18 and 19) and four initially likely pathogenic as pathogenic (in patients 5, 6, 
12, and 13). 
We have previously shown that HTS technologies can successfully be applied to 
diagnose inherited bleeding, platelet and thrombotic disorders (Simeoni, et al 2016). In 
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the present study, a total of 23 patients, 12/19 initially coded as “unclassified platelet 
disorder” and 11/11 for whom only a suspicion of MYH9-RD was put forward with no 
conclusive diagnosis, received a molecular diagnosis of MYH9-RD because a likely 
pathogenic or pathogenic variant in MYH9 was found. 
Our data confirm that the presence of Döhle-like bodies is an invariable feature of MYH9-
RD. Indeed, Döhle-like bodies were found in all 18 patients that were re-analysed by 
immunofluorescence (in 9 patients with a pathogenic, in 5 patients with a likely 
pathogenic and in 4 patients with a VUS variant) and in 11/18 by MGG (in 6 patients 
with a pathogenic, in 4 patients with a likely pathogenic and in a single patient with a 
VUS variant) bringing the percentage of patients positive for Döhle-like bodies inclusion 
and with a variant in the MYH9 to 100%. Interestingly, we noted that 52% (11 out of the 
21) of the patients in which Döhle-like bodies were reported at enrollment by MGG 
staining had a variant in the tail or in the S2 fragment, which are the regions of the 
MYH9 protein that, when mutated, are associated with the presence of type I inclusions, 
the most visible at MGG staining and more easy to identify. Our attempt to identify 
genotype/phenotype correlations in this cohort of patients generally confirms previously 
published data (Pecci, et al 2014, Pecci, et al 2008b, Saposnik, et al 2014), although with 
some exceptions. Our study confirms that variants in the HD are frequently associated 
with more severe thrombocytopenia and higher risk of other organ involvement contrarily 
to variants in the TD. In fact, two patients (cases 8 and 10) with severe/moderate 
thrombocytopenia, kidney disease and hearing impairment had variants in the HD (exon 
2 and 17 respectively), while most of the cases with variants in the TD showed mild 
thrombocytopenia and no extra-haematological organ involvement. Regarding the 
exceptions, three patients in our series carrying variants in the HD (patients 11, 12 and 
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13) had only mild thrombocytopenia, very mild or absent bleeding symptoms, and no 
other extra haematological manifestations, except hearing loss in patient 12. Moreover, 
four patients in our cohort (cases 28, 30, 33 and 50) with variants in the TD had severe 
thrombocytopenia (≤20x109/L). Also patients carrying the same variant (p.Ser96Leu and 
p.Arg718Trp) did not share the same extra-hematological phenotype, showing that the 
risk of developing deafness or renal failure may be variable among patients carrying the 
same variant. The risk to develop these phenotypes is known to increase with age. In our 
cohort we did not observe a clear age-dependency for the development of an extra-
hematological phenotype, however, it must be considered that our patients are mostly 
relatively young. For instance, patients 12 and 13 with the p.Arg702Cys variant are 7 and 
11 years old, respectively. Their health care management will take in consideration the 
high risk of developing extra-hematologic features by age of 40 due to this known 
pathogenic variant.  
Our cohort confirms that the presence of macrothrombocytes is an invariable feature of 
this disorder while thrombocytopenia, although highly frequent, may be absent (Pecci, et 
al 2014, Saposnik, et al 2014). This is the case for patients 17 and 40, with a platelet 
count of 187 and 220 x109 /L, respectively. Patient 17 shares the same variant with her 
sister (patient 14), her nephew (patient 15) and her mother (patient 16) who have all three 
mild thrombocytopenia. Unfortunately, we could not investigate further patient 40. Thus, 
this cohort confirms that a wide platelet count variability is a feature of MYH9-RD 
(Balduini, et al 2011). In conclusion, our study expands the number of variants causing 
MYH9-RD, highlights the heterogeneity of the MYH9-RD phenotypes and, despite 
supporting previous correlation studies, shows that exceptions exist in 
genotype/phenotype correlations. The application of HTS-based strategies revealed to be 
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a reliable and fast method to reach a conclusive diagnosis of MYH9-RD and exclude 
other thrombocytopenias with potential susceptibility to malignancies and may represent 
the first line of investigation for this disorder, even after preliminary expert evaluation.  
Acknowledgements 
We are grateful to patients who accepted to participate in these projects. We would like to 
thank all the members of the BRIDGE-BPD and ThromboGenomics Consortia for their 
valuable contributions. In particular, Veerle Labarque from Leuven for recruiting patients 
for the ThromboGenomics panel, and Dr Romina Petersen for helping with data analysis. 
We thank Anna Maria Mezzasoma (University of Perugia, Italy) for the help with MGG-
staining and analysis of blood smears. We gratefully acknowledge the participation of all 
NIHR BioResource volunteers, and thank the NIHR BioResource centre and staff for 
their contribution. We thank the National Institute for Health Research and NHS Blood 
and Transplant.  
Authorship Contribution 
L.B. wrote the paper, performed immunofluorescence and provided samples; K.M. 
reviewed the paper, managed data, set up and oversaw MDT meetings; J.C.S. provided 
genotyping results and processed samples; L.G. provided BLUEPRINT data; D.G. 
performed statistical analysis and provided HPO tables; N.G. performed variant 
conservation analysis; K.A. and L.B. performed immunofluorescence; D.A., T.K.B, 
M.B., N.V.B., P.C., N.C., K.E., E.F, B.F., D.K., C.M.M., M.P.L, S.M., D.J.P., S.S, 
S.K.W., K.F., K.G., L.B. and P.G. provided samples and clinical data; S.V.V.D supported 
the bioinformatics analysis, K.D. managed ThromboGenomics; R.M. performed DNA 
extraction; D.D processed ThromboGenomics samples, S.P. coordinated the NIHR 
This article is protected by copyright. All rights reserved. 
 A
cc
ep
te
d 
A
rt
ic
le
 
BioResource Rare Diseases BPD project; C.P. managed and supervised the WGS 
pipeline; K.S. managed the NIHR BioResource sequencing pipeline; E.T. managed 
BRIDGE-BPD data analysis; K.F. and K.G. chaired the MDT meetings; P.G., K.F. and 
W.H.O. reviewed the paper; I.S. wrote the paper, managed and processed 
ThromboGenomics samples. 
Data Availability Statement 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request. 
Table 1. 
List of variants with nucleotide change position, protein alteration and allele frequency. 
Cases labelled from 1 to 50. Ethnicity indicated when known. MTD outcome is shown 
per each variant as pathogenicity and contribution to phenotype. ACMG= American 
College of Medical Genetics; CADD=Combined Annotation Dependent Depletion; 
MDT= Multi-Disciplinary Team; EUR= European; SAS= South Asian; AFR= African; 
VUS= Variant of Uncertain Significance; ExAC= Exome Aggregation Consortium; 
gnomAD = Genome Aggregation Database. 
Figures 
Figure 1. Schematic representation of the heavy chain A of non-muscle myosin class 
IIA (NMMHC-IIA) and variants position.  
A. Schematic representation of NMMHC-IIA protein. Non-muscle myosin II A shows 
a hexameric structure consisting of two heavy chains, namely NMMHC-IIA, and two 
pairs of light chains. Each heavy chain includes a N-terminal globular head domain (HD), 
a neck region which binds the light chains, and a C-terminal α-helical coiled-coil tail 
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domain (TD), which ends with a non-helical tail domain (NHTD) involved in the 
subcellular localization of the protein. The HD includes four subdomains: the N-terminal 
SRC-Homology 3 like motif (SH3), the upper and lower 50kDa subdomains, that 
together form the motor domain (MD), and the converter subdomain. 
In green the globular HD, in violet the neck domain and in blue the coiled coil TD with 
the NHTD at the 3’UTR in orange. B. Affected exons and variants identified. The most 
affected exons are highlighted with red stars. The novel variants are shown in bold and 
the number in brackets is the patient ID number. Colors reflect protein domains. All 
variants described were confirmed by Sanger sequencing. The * indicates the two 
mutations identified in the same patient (39). #*,^,ᐤ,ᐥ represent members of the same 
family. 
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Figure 2. Evolutionary conservation variant analysis. From the outer to the inner 
circle. MYH9 protein domains: in green the N-terminal globular head domain (HD), in 
purple the neck domain, in blue the C-terminal α-helical coiled-coil tail domain (TD) and 
in orange the 3’UTR. Evolutionary conserved regions in the MYH9 protein in grey. 
All the pathogenic, likely pathogenic and VUS variants affect highly conserved amino 
acid residues. Variant minor allele frequency (MAF) in gnomAD database is 
represented by green bars. Smaller is the green bar lower is the allele frequency. 
Variants present in ClinVar and LOVD are represented by blue bars. The height of 
each blue bar represents the number of patients previously described with the same 
variant. Variants in this cohort previously seen in the literature include ‘clearly 
pathogenic’ and ‘likely pathogenic’ variants, in red and orange, respectively. Novel 
variants in this cohort include ‘likely pathogenic” variants and variants of uncertain 
significance (VUS) in orange and black, respectively. UTR= Untranslated region. 
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Figure 3. Döhle-like inclusion bodies localization by NMMHC-IIA 
immunofluorescence or MGG staining. Light microscopy and immunofluorescence 
analyses of granulocytes in a healthy control (control), in patients (32 for 
immunofluorescence, 43 for light microscopy) with a pathogenic variant (pathogenic) 
and in three patients (28, 29 and 40) with a variant of uncertain significance (VUS). The 
analysis was performed by two independent centres: Panels I-V show results obtained by 
centre 1; Panels VI-X show results obtained by centre 2. Both centres used rabbit anti-
human NMMHCIIA Ab followed by Alexa-Fluor 488-conjugated secondary antibody. 
Results between the two centers were highly comparable. The patient’s sample in which a 
pathogenic variant was identified shows circular to oval shaped cytoplasmic punctuate 
spots, classified as type II inclusions (panels II and VII). Patients’ samples in which 
VUSs were identified show a speckled staining (panels III and VIII and panels V and X, 
respectively), and many small dots scattered throughout the cytoplasm (panels IV and IX) 
classified as type III inclusions.  
Panels XI-XV show May Grunwald-Giemsa staining. Panels XII and XV show the 
presence of Döhle-like bodies (arrowhead) in patients’ samples with a pathogenic variant 
(XII) and a VUS (XV). NMMHCIIA= non-muscle myosin of class IIA. VUS= Variant of 
Uncertain Significance. 
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Figure 4. Cohort Phenotype. A) HPO terms coded for haematological and B) non-
haematological symptoms. Y axis: HPO terms; X axis: patient ID number (from 1 to 
50). Red box: presence of the phenotypic feature; green box: presence of NMMHC-IIA 
aggregates identified only after centralized immunofluorescence analysis; blue box: data 
not available. Pale yellow box: absence of phenotypic feature. NMMHCIIA = non-
muscle myosin of class IIA. 
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Table I - MYH9 variants 
Patie
nt 
Ethnic
ity 
Chromo
somal 
position 
(NG_011
884.2) 
Transcript 
alteration 
(NM_002473.5) 
Protein 
alteration 
(NP_0024
64.1) 
MY
H9 
do
ma
in 
aff
ect
ed 
Vari
ant 
typ
e 
C
A
D
D 
sc
or
e 
AF 
(Ex
AC 
and 
gno
mA
D) 
 
Path
ogeni
city 
and 
contr
ibutio
n to 
phen
otype 
 
ACMG 
Evide
nces 
 
Diag
nosi
s 
Novel MYH9 variants 
1 EUR 22:4387
9T>G  c.97T>G 
p.(Trp33G
ly) HD 
mis
sen
se 
27
.2
0 
Not 
pre
sent 
Likely 
patho
genic 
Full 
PM2, 
PM5, 
PP3, 
PP4, 
A 
New 
diag
nosi
s 
MYH
9-RD 
not 
susp
ected 
2 EUR 
22:4389
0_43898
del 
 
c.108_116delCGACA
AGAG 
p.(Asp37_
Ser39del) HD 
infr
ame 
dele
tion 
N/
A 
Not 
pre
sent 
VUS 
Full 
PM2, 
PM4, 
PP4, 
A 
 
Kno
wn 
MYH
9-
RD 
Patie
nt 
with 
no 
genet
ic 
confir
matio
n 
3 EUR 22:43904T>C  c.122T>C 
p.(Phe41S
er) HD 
mis
sen
se 
28
.7 
Not 
pre
sent 
VUS 
Full 
PM6, 
PM2, 
PP3, 
PP4, 
A 
 
No 
diag
nosi
s 
Assu
med 
de 
novo 
varia
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20 EUR 22:91998del c.2668delC 
p.(Gln890
Arg*) TD 
sto
p-
gai
n 
N/
A 
Not 
pre
sent 
VUS� 
Full 
PM2, 
PVS1,  
PP4, 
A  
 No 
diag
nosi
s 
39 EUR 22:92091G>A c.2761G>A 
p.(Glu921
Lys) TD 
mis
sen
se 
33 
1:1
00,
000 
(Ex
AC 
and 
gno
mA
D) 
VUS 
Full 
PM2, 
A, B 
No 
diag
nosi
s 
21 EUR 
22:9610
6_96126
dup 
c.3202_3222dupCA
GGCCCAGATCGCG
GAGCTC 
p.(Gln106
8_Leu107
4dup) 
TD 
infr
ame 
inse
rtio
n 
N/
A 
Not 
pre
sent 
VUS 
Full 
PM2, 
PM4, 
PP4, 
A, B 
 
Kno
wn 
MYH
9-
RD 
Patie
nt 
with 
no 
genet
ic 
confir
matio
n 
28 EUR 22:98041C>T  c.3584C>T 
p.(Ser119
5Leu) TD 
mis
sen
se 
23
.1 
Not 
pre
sent 
VUS 
Full 
PM2, 
A 
No 
diag
nosi
s 
 
29 
 
EUR 22:100951A>C c.4262A>C 
p.(Glu142
1Ala) TD 
mis
sen
se 
28
.5 
Not 
pre
sent  
VUS 
Full 
PM2, 
PP3, 
A 
No 
diag
nosi
s 
 
37 
 
AFR 22:100991G>C  c.4302G>C 
p.(Gln143
4His) TD 
mis
sen
se 
23
.5 
1:1
0,0
00 
(Ex
AC)
; 
1:2
50,
000 
VUS 
Full 
PM2 
No 
diag
nosi
s 
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(gn
om
AD) 
39 EUR 22:1061
86A>G 
 c.4946A>G p.(Asp1649Gly) TD 
mis
sen
se 
32 
Not 
pre
sent 
VUS 
Full 
PM2, 
PP3, 
PP1, 
A, B 
No 
diag
nosi
s 
40 N/A 22:106272A>G  c.5032A>G 
p.(Met167
8Val) TD 
mis
sen
se 
18
.4 
Not 
pre
sent 
VUS 
Uncer
tain 
PM2, 
A 
 
No 
diag
nosi
s 
50 N/A 22:110276del  c.5808delG 
p.(Gly193
8Alafs*10) 
NH
TD 
fra
mes
hift 
N/
A 
Not 
pre
sent 
Likely 
patho
genic 
Full 
PM2, 
#PM4, 
PM1, 
PP4, 
A  
Kno
wn 
MYH
9-
RD 
Patie
nt 
with 
no 
genet
ic 
confir
matio
n 
 
Known MYH9 variants 
 
4 EUR 22:44002A>G  c.220A>G 
p.(Lys74Gl
u) 
(Kanematsu
, et al 2016) 
HD 
mis
sen
se 
23
.5
0 
Not 
pre
sent 
Likely 
patho
genic 
Full 
PS4_s
upporti
ng, 
PM2, 
PP4, 
PP3, 
A, B 
Kno
wn 
MYH
9-
RD 
patie
nt 
5 EUR 22:.44061C>G c.279C>G 
p.(Asn93L
ys) 
(Seri, et al 
2000) 
HD 
mis
sen
se 
25 
Not 
pre
sent 
**Pat
hoge
nic 
Full 
PS4, 
PS3, 
PM1, 
PM2, 
PP4, 
PP3, 
A 
Kno
wn 
MYH
9-
RD 
patie
nt 
6 EUR 22:.44065G>A c.283G>A 
p.(Ala95Th
r) 
(Kunishima, 
et al 2001b) 
HD 
mis
sen
se 
29
.7
0 
Not 
pre
sent 
**Pat
hoge
nic 
Full 
PS4, 
PM6, 
PM2, 
PM1, 
PP3, 
A 
New 
diag
nosi
s 
MYH
9-RD 
susp
ected 
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med 
de 
novo 
varia
nt 
 
7,8,9
, 
10 
EUR7,
8,N/A9, 
Hispan
ic10 
22:4406
9C>T c.287C>T 
p.(Ser96Ly
s) 
(Arrondel, et 
al 2002)  
HD 
mis
sen
se 
32
.0
0 
Not 
pre
sent 
Patho
genic 
Full 
PS4, 
PM1, 
PM2, 
PP4, 
PP3, 
A8,10 
New 
diag
nosi
s for 
patie
nts 
7, 8 
and 
9. 
Patie
nts 7 
and 9 
(MYH
9-RD 
not 
susp
ected
); 8 
(susp
ected
); 
10 
(kno
wn 
MYH
9-
RD). 
11 EUR 22:74704G>C c.1119G>C 
p.(Lys373
Asn) 
(Arrondel, et 
al 2002)  
HD 
mis
sen
se 
28
.8 
Not 
pre
sent 
Likely 
patho
genic 
Full 
PS4, 
PM2, 
PP4, 
PP3, 
A 
 
New 
diag
nosi
s 
MYH
9-RD 
susp
ected 
12, 
13 
East 
Asian1
2, 
EUR13 
22:8703
4C>T c.2104C>T 
p.(Arg702
Cys) 
(Seri, et al 
2000) 
HD 
mis
sen
se 
35 
Not 
pre
sent 
**Pat
hoge
nic 
Full 
PS4, 
PS3, 
PM2, 
PP4, 
PP3, 
A12 
 
New 
diag
nosi
s for 
patie
nt 13  
Patie
nts 
13 
(MYH
9-RD 
susp
ected
); 12 
(kno
wn 
MYH
9-
RD) 
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16#,
17# 
EUR14
,15,16,1
7 
22:8708
2C>T c.2152C>T 
p.(Arg718
Trp) 
(Pecci, et al 
2008b) 
 
HD 
mis
sen
se 
34 
Not 
pre
sent 
in 
ExA
C; 
1:2
50,
000 
(gn
om
AD) 
Patho
genic 
Full 
PS4, 
PM2, 
PP1_s
trong, 
PP4, 
PP3, 
A17,B1
4,15,16
,17 
 
New 
diag
nosi
s for 
all 
patie
nts 
MYH
9-RD 
susp
ected 
 
18,1
9 
EUR18
,19 
22:9136
1C>T 
 
c.2507C>T 
p.(Pro836
Lys) 
(Neveling, et 
al 2013) 
TD 
mis
sen
se 
34 
Not 
pre
sent 
*Likel
y 
patho
genic 
Full 
PS4, 
PM2, 
PP4, 
PP3, 
A18 
New 
diag
nosi
s for 
both 
patie
nts  
Patie
nts 
18 
(MYH
9-RD 
susp
ected
); 19 
(not 
susp
ected
) 
22^,
23, 
24^,
25, 
26,2
7 
EUR22
,23,24,2
6,27 
N/A25 
22:9795
0C>T c.3493C>T 
p.(Arg116
5Cys) 
(Seri, et al 
2000) 
TD 
mis
sen
se 
34 
Not 
pre
sent 
Patho
genic 
Full 
PS4, 
PM2, 
PP1_s
trong, 
PP4, 
PP3, 
A25, 
B22-24 
New 
diag
nosi
s for 
patie
nts 
23,2
5,26,
27 
Patie
nts 
23 
and 
25 
(MYH
9-RD 
susp
ected
); 26 
and 
27 
(not 
susp
ected
); 22 
and 
24 
(kno
wn 
MYH
9-
RD) 
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30,3
1, 
32,3
3 
Iraqui3
0, 
N/A31, 
SAS32, 
Hispan
ic33 
22:1009
59G>A c.4270G>A 
p.(Asp142
4Asn) 
(Kunishima, 
et al 2001a) 
TD 
mis
sen
se 
33 
Not 
pre
sent 
Patho
genic 
Full 
PS4, 
PP1_s
trong, 
PM2, 
PP4, 
PP3, 
A31,33 
New 
diag
nosi
s for 
all 
patie
nts  
Patie
nts 
31, 
32, 
33 
(MYH
9-RD 
susp
ected
); 30 
(not 
susp
ected
)  
34�,
35�,
36 
EUR34
,35,36 
22:1009
59G>T c.4270G>T 
p.(Asp142
4Tyr) 
(Kunishima, 
et al 2001b) 
TD 
mis
sen
se 
32 
Not 
pre
sent 
Patho
genic 
Full 
PS4, 
PP1_s
trong, 
PM2, 
PP4, 
PP3, 
A, 
B34-35 
New 
diag
nosi
s for 
patie
nt 36  
Patie
nt 36 
(MYH
9-RD 
susp
ected
); 34 
and 
35 
(kno
wn 
MYH
9-
RD) 
 
38 EUR 22:101029A>T c.4340A>T 
p.(Asp144
7Val) 
(Pecci, et al 
2008b) 
TD 
mis
sen
se 
31 
Not 
pre
sent 
Likely 
patho
genic 
Full 
PS4, 
PM2, 
PP4, 
PP3, 
A, B 
Kno
wn 
MYH
9-
RD 
patie
nt 
with 
no 
gene
tic 
confi
rmati
on 
41,4
2, 
43�, 
EUR42
,44,45, 
22:1085
45G>A c.5521G>A 
p.(Glu184
1Lys) TD mis
sen
34 Not 
pre
Patho
genic 
PS4, 
PP1_s
trong, 
Kno
wn 
MYH
9-
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44� Filipino
43 
 
(Seri, et al 
2000) 
se sent Full PM2, 
PP4, 
PP3, 
A41-
44, 
B43,44 
RD 
Patie
nts 
with 
no 
genet
ic 
confir
matio
n 
45 EUR 
22:1102
38_1102
47del 
c.5770_5779delGGG
GACCTGC 
p.(Gly1924
Argfs*21) 
(Pecci, et al 
2010b) 
NH
TD 
fram
eshi
ft 
36 
1:5
0,0
00 
(Ex
AC)
; 
not 
pre
sent 
in 
gno
mA
D 
Patho
genic 
Full 
PS4, 
#PM4, 
PM2, 
PM1, 
PP4, 
A 
New 
diag
nosi
s 
MYH
9-RD 
not 
susp
ected 
46,4
7,48 N/A 
22:1102
65C>T c.5797C>T 
p.(Arg193
3*)  
(Seri, et al 
2000) 
NH
TD 
stop
-
gain 
50 
1:1
00,
000 
(Ex
AC)
; 
1:2
50,
000 
(gn
om
AD) 
Patho
genic 
Full 
PS4, 
PM2, 
PM1, 
PP4, 
A46-48 
B47 
Kno
wn 
MYH
9-
RD 
Patie
nts 
with 
no 
genet
ic 
confir
matio
n 
49 EUR 22:110268del c.5800delA 
p.(Met193
4Trpfs*14) 
(Savoia, et 
al 2010) 
NH
TD 
fram
eshi
ft 
34 
Not 
pre
sent 
Likely 
patho
genic 
Full 
PS4, 
#PM4, 
PM2, 
PM1, 
PP4, 
A 
Kno
wn 
MYH
9-
RD 
Patie
nt 
with 
no  
genet
ic 
confir
matio
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ACMG Guidelines Evidences: PVS1 (very strong evidence): Null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation 
codon, single or multi-exon deletion) in a gene where LOF is a known mechanism of disease; PS1 (strong evidence): same amino acid 
change as a previously published pathogenic variant regardless of nucleotide change; PS4 (strong evidence): The prevalence of the variant in 
affected individuals is significantly increased compared with the prevalence in controls; PS3 (strong evidence): Well-established in vitro or in 
vivo functional studies supportive of a damaging effect on the gene or gene product; PM2 (moderate evidence): Absent from controls (or at 
extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium; PM1 
(moderate evidence): Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) 
without benign variation; PM4 (moderate evidence): Protein length changes as a result of in-frame deletions/insertions in a non repeat 
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region or stop-loss variants; PM6 (supporting evidence): Assumed de novo, but without confirmation of paternity and maternity; PP2 
(supporting evidence): Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a 
common mechanism of disease; PP3 (supporting evidence): Multiple lines of computational evidence support a deleterious effect on the 
gene or gene product (conservation, evolutionary, splicing impact, etc.), ; PP1 (supporting evidence): Cosegregation with disease in multiple 
affected family members in a gene definitively known to cause the disease; PP4 (supporting evidence): Patient's phenotype or family history 
is highly specific for a disease with a single genetic etiology; #PM4 used instead of PVS1 in case of protein termination within the last 50 
amino acids; A: presence of at least one main MYH9-RD feature in addition to macrothrombocytes (Dohle-like bodies, hearing impairment, 
nephropathy, alteration of liver enzymes); B: family history of MYH9-RD. 
The ACMG evidence PP3 is used only in case of all the following evidences are present: highly conserved nucleotide, highly conserved amino 
acid, effect on protein, alignment with GVGD of C65 and deleterious prediction in SIFT, Mutation Taster and PolyPhen.  
Superscript numbers in the ‘Ethnicity’ and in the ‘ACMG Evidences’ columns represent the patients. *Variant initially considered as ‘VUS’ but 
then changed into ‘likely pathogenic’; ** Variants initially labelled as ‘likely pathogenic’ and subsequently re-classified as ‘pathogenic’; variant 
labelled as VUS, independently by the ACMG evidences, due to the impossibility to perform functional tests. 
Members of the same family are represented with the following symbols: #,^,ᐤ,ᐤ  
HD= head domain; TD=coiled-coil tail domain; NHTD = non-helical tail domain. 
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